Comparative Pharmacology
Head-to-head clinical analysis: K LEASE versus KLOR CON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: K LEASE versus KLOR CON.
K-LEASE vs KLOR-CON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Potassium ion replacement therapy; increases extracellular potassium levels to correct hypokalemia.
Potassium chloride acts as a source of potassium ions, which are essential for maintenance of intracellular tonicity, transmission of nerve impulses, contraction of cardiac, skeletal, and smooth muscle, and maintenance of normal renal function. Potassium is the major cation of intracellular fluid and helps regulate acid-base balance.
1 tablet (25 mEq) orally 2-4 times daily with meals; maximum 100 mEq/day.
Potassium chloride extended-release: 20-100 mEq per day orally, divided into 2-4 doses, titrated based on serum potassium and clinical response. Usual starting dose: 40 mEq per day.
None Documented
None Documented
Not applicable; exogenous potassium is not subject to terminal elimination half-life as it is rapidly redistributed and excreted. Clinical context: the half-life of redistribution is minutes to hours.
The terminal elimination half-life of potassium is approximately 1-1.5 hours in healthy individuals with normal renal function. In patients with impaired renal function, half-life may be prolonged, increasing the risk of hyperkalemia.
Excreted renally as potassium chloride; elimination is 100% renal. No biliary or fecal excretion.
Renal excretion of potassium ions accounts for approximately 90% of elimination via the kidneys, with the remaining 10% eliminated fecally. No biliary excretion is clinically significant.
Category C
Category C
Potassium Supplement
Potassium Supplement